HematologyNews.net

Hematology Xagena

Search results for "Keytruda"

Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, has achieved an overall response rate of 66%, as assessed by International Harmonization Project response criteria ( n=19/29: 95% CI, 46-82 ), in tran ...


Merck, known as MSD outside the United States and Canada, has announced new study findings investigating the use of Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, in combination with Lenalidomide a ...


The findings from KEYNOTE-087, the phase 2 study investigating the use of Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, as a monotherapy in patients with relapsed or refractory classical Hodgkin l ...


Immunotherapy in multiple myeloma is emerging as an effective modality in therapy of multiple myeloma with the approval of several monoclonal antibodies and encouraging results for vaccines and T cell ...


Modern therapy for multiple myeloma including generations of Thalidomide analogues, proteasome inhibitors and alkylating agents has substantially improved the survival for this disease. Patients who ...